INTRODUCTION {#S1}
============

Both gain and loss of function of developmental regulator Polycomb repressive complex 2 (PRC2) are found in cancer, including leukemia and lymphoma. The underlying mechanisms are incompletely understood. PRC2 consists of the core subunits Extraembryonic Ectoderm Development (*EED*), Suppressor of Zeste 12 (*SUZ12*), and the methyltransferase Enhancer of Zeste 2 (*EZH2*) (reviewed in [@R28]). High-level expression of *EZH2* has been described in prostate cancer and other epithelial malignancies ([@R63]), and hyperactive mutants of *EZH2* have been identified in diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL) ([@R43]; [@R55]). On the other hand, *EZH2* is somatically inactivated in other hematological malignancies, including myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN), and CALM-AF10 leukemia ([@R14]; [@R16]; [@R17]; [@R39]). PRC2 components are also inactivated by mutation in T-lineage acute lymphoblastic leukemia (ALL) ([@R41]), and especially in the aggressive subtype early T cell precursor (ETP)-ALL ([@R70]). Alterations of the methyltransferase EZH2 in particular have been linked to poor clinical outcomes in this disease ([@R70]).

Data from animal models have provided some insight into the role of PRC2 in normal development and malignancy without resolving how both gain and loss of function of PRC2 contribute to the development of hematologic malignancies. The PRC2 core components *Ezh2*, *Suz12*, and *Eed* are required for proper differentiation of mouse embryonic stem cells ([@R45]; [@R51]). The causal involvement of hyperactive *Ezh2* mutations in lymphomagenesis has been demonstrated in mice ([@R1]; [@R4]). At the same time, *Ezh2* is required for proper B and T cell development ([@R58]). Inactivation of *Ezh2* is partially compensated in some contexts by the less well-characterized methyltransferase EZH1 ([@R30]; [@R51]), whereas inactivation of *Eed* leads to complete loss of the canonical PRC2 function and di- and tri-methylation of lysine 27 on histone 3 ([@R51]; [@R67]). Inactivation of *Ezh2* and *Eed* both impair the growth of murine models of *MLL*-rearranged acute myeloid leukemia (AML), and this effect has been ascribed in part to derepression of the *Cdkn2a* tumor suppressor encoding *p16^ink4a^* and *p19^arf^* ([@R37]; [@R52]). In contrast, inactivation of *Ezh2* in mice has led to T cell leukemia ([@R54]) and MDS/MPN-like conditions ([@R36]). To better understand how PRC2 functions as a tumor suppressor in ETP-ALL, we developed a murine model that recapitulates features of human ETP-ALL and directly compared leukemias with and without inactivation of *Ezh2 and Eed*.

RESULTS {#S2}
=======

*NRASQ61K*-Expression in *Cdkn2a*^−/−^ Stem/Progenitor Cells Cooperates with Homozygous *Ezh2* or *Eed* Inactivation in Leukemogenesis {#S3}
--------------------------------------------------------------------------------------------------------------------------------------

Human ETP-ALL is an aggressive subtype of ALL and has been linked to a stem-cell-like gene-expression program ([@R70]). Genetic changes occurring in ETP-ALL are heterogeneous, with inactivating mutations of PRC2-components occurring frequently and being linked to poor clinical outcomes ([@R70]). We sought to study the role of *Ezh2* in a mouse model mediated by genetic alterations found in human ETP-ALL. Many cases of ETP-ALL have alterations that directly (e.g., oncogenic mutations) or indirectly (e.g., NF1-inactivation) activate RAS signaling. *Cdkn2a* mutations/deletions are encountered in a subset of ETP-ALL. Among 64 ETP cases in the St. Jude study, there are 11 NRAS mutated ETP cases. 5 of the 11 NRAS mutant ETP cases have alterations in at least one PRC2 component ([@R70]).

To model human ETP-ALL, we introduced oncogenic *NRASQ61K* and a self-excising hit-and-run Cre or an inert GFP-expressing control vector (MSCV-ires-GFP = MIG) into *Ezh2^f/f^ Cdkn2a*^−/−^ *ROSA26lox-Stop-loxYFP* lineage-negative, SCA1-positive, and KIT-positive (LSK) cells ([@R37]; [@R50]; [@R56]). Cells were expanded in the presence of cytokines promoting lymphoid development (SCF, FLT3L, and IL7) on OP9-DL1, a feeder cell line providing a Notch signal by expressing Delta-like 1 ligand. We chose a time window of 14 days to allow for expansion of cells and to approximate the time window ([@R49]) reported to allow for T-lineage differentiation from immature hematopoietic cells using OP9-DL1 cells ([Figure 1A](#F1){ref-type="fig"}). Cells grown in this manner for 14 days demonstrated a phenotype consistent with murine double-negative (DN) 1 and 2 cells in the setting of *Ezh2* inactivation, whereas the floxed counterparts showed a majority of cells progressing to the DN3 stage ([Figures S1A--S1C](#SD1){ref-type="supplementary-material"}). Cells also had a surface marker profile consistent with human ETP leukemia, with subsets staining positive for MAC1 and/or GR1 ([Figure S1D](#SD1){ref-type="supplementary-material"}), CD5 ([Figure S1E](#SD1){ref-type="supplementary-material"}), and KIT ([Figure S1F](#SD1){ref-type="supplementary-material"}). *Ezh2^f/f^ and Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells were transplanted into recipient mice to interrogate their leukemogenic potential.

Cre-transduced *NRASQ61K Ezh2^f/f^ Cdkn2a*^−/−^ *ROSA26lox-Stop-loxYFP* cells were found to have fully excised floxed *Ezh2*-sequences at the time of injection ([Figure S2A](#SD1){ref-type="supplementary-material"}). In contrast, co-transduction of *NRASQ61K* and Cre into LSK cells with an intact *Cdkn2a* locus (*Ezh2^f/f^ Cdkn2a^+/+^* LSK cells) resulted in outgrowth of incompletely *Ezh2*-excised cells ([Figure S2B](#SD1){ref-type="supplementary-material"}), and these cells were not transplanted in vivo. We documented loss of EZH2 in *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells at the protein level ([Figure S2C](#SD1){ref-type="supplementary-material"}). Excision of floxed *Ezh2* sequences led to globally reduced H3K27me2 ([Figure S2D](#SD1){ref-type="supplementary-material"}) and H3K27me3 ([Figure 1B](#F1){ref-type="fig"}) in *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells compared to *Ezh2^f/f^ Cdkn2a*^−/−^ *NRASQ61K* cells.

Transplantation of *NRASQ61K*-transduced cells resulted in leukemia with 100% penetrance in the presence or absence of functional *Ezh2*; however, inactivation of *Ezh2* resulted in significantly shortened latency ([Figure 1C](#F1){ref-type="fig"}). Sustained complete excision of floxed *Ezh2* sequences was documented in vivo by RNA-seq ([Figure S2E](#SD1){ref-type="supplementary-material"}) and by qRT-PCR ([Figures S2F and S2G](#SD1){ref-type="supplementary-material"}). Inactivation of the PRC2 component *Eed* (*Eed*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K*) also resulted in significantly shortened eukemia latency ([Figure 1D](#F1){ref-type="fig"}). Latency of *Eed*-inactivated and *Ezh2*-inactivated *NRASQ61K* leukemias on a *Cdkn2a*^−/−^ background was very similar in a direct comparison ([Figure 1E](#F1){ref-type="fig"}). Excision of floxed *Eed* sequences was confirmed by qRT-PCR ([Figure S2H](#SD1){ref-type="supplementary-material"}). Inactivation of *Eed* resulted in an expected global cellular loss of H3K27me3 ([Figure S2I](#SD1){ref-type="supplementary-material"}).

*NRASQ61K* Leukemia Shares Phenotypic Features with Human ETP-ALL {#S4}
-----------------------------------------------------------------

In addition to a shortened latency for leukemias with compromised PRC2 function, we observed subtle phenotypical differences that are consistent with more aggressive and immature disease. Recipients of *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells had significantly higher peripheral white blood cell counts and a trend toward lower hemoglobin and platelet counts ([Figure S2J](#SD1){ref-type="supplementary-material"}). Engraftment in the bone marrow ([Figure S3A](#SD1){ref-type="supplementary-material"}) of moribund mice was also higher in the *Ezh2*^D/D^ and *Eed*^D/D^ groups compared to floxed counterparts. There was no clear trend for splenic involvement: spleen weight ([Figure S3B](#SD1){ref-type="supplementary-material"}) was similar in the *Ezh2*^D/D^ and slightly but significantly lower in the *Eed*^D/D^ group; however, engraftment was higher in the *Ezh2*^D/D^ and *Eed*^D/D^ groups compared to floxed counterparts ([Figure S3C](#SD1){ref-type="supplementary-material"}). We found a non-significant trend toward lower thymus weights ([Figure S3D](#SD1){ref-type="supplementary-material"}) and significantly lower thymic engraftment ([Figure S3E](#SD1){ref-type="supplementary-material"}) in the *Ezh2*^D/D^ and *Eed*^D/D^ groups, which is in keeping with a low frequency of mediastinal tumors in human ETP-ALL ([@R8]).

Floxed, *Ezh2*^D/D^, and *Eed*^D/D^ splenic blasts had a similar immunophenotype, with minor differences. All three groups had a similar proportion of blasts with at least one myeloid marker (MAC1 or GR1; [Figure S3F](#SD1){ref-type="supplementary-material"}). *Ezh2*^D/D^ *Cdkn2a*^−/−^ blasts had a higher proportion of blasts double positive (DP) for both MAC1 and GR1 ([Figure 2A](#F2){ref-type="fig"}). Common to all three groups was a majority of leukemia cells with a CD44-positive/CD25-negative surface phenotype ([Figure 2B](#F2){ref-type="fig"}; similar to thymic DN1 cells). We also observed subset positivity for the lymphoid marker CD5 ([Figure 2C](#F2){ref-type="fig"}) and for c-KIT ([Figure 2D](#F2){ref-type="fig"}). The phenotype of *Ezh2^f/f^* *Cdkn2a*^−/−^ and *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* leukemias was also similar with respect to expression of additional lymphoid surface markers ([Figures S3G and S3H](#SD1){ref-type="supplementary-material"}). However, *Ezh2^f/f^* *Cdkn2a*^−/−^ cells had a higher proportion of CD8 single-positive cells ([Figures S3I--S3L](#SD1){ref-type="supplementary-material"}), consistent with a less stringent differentiation block. In summary, NRASQ61K-transformed murine LSK cells with an inactivated *Cdkn2a* locus form an acute leukemia in mice that shares phenotypic features with human ETP-ALL.

*Ezh2*-Inactivation Accentuates Transcriptional Programs Characteristic of ETP-ALL and of Normal Murine Early Thymic Precursors {#S5}
-------------------------------------------------------------------------------------------------------------------------------

To characterize the effects of *Ezh*2-inactivation on a molecular level, we performed global expression profiling by RNA-seq of *Ezh2*^D/D^ and *Ezh2^f/f^ Cdkn2a*^−/−^ NRASQ61K cells both in vitro prior to transplantation and in vivo after harvest from leukemic spleens. Genes with increased expression in human ETP-ALL compared to typical T-lineage ALL ([@R70]) were significantly enriched in *Ezh2*^D/D^ cells compared to *Ezh2^f/f^* counterparts ([Figure 2E](#F2){ref-type="fig"} in vivo; [Figure S3M](#SD1){ref-type="supplementary-material"} in vitro). We also evaluated the expression of genes characteristic of purified, untransformed murine CD4/CD8 DN1 ETP cells compared to CD4/CD8 DP cells ([@R71]). This gene set was found to be enriched in *Ezh2*^D/D^ compared to *Ezh2^f/f^ Cdkn2a*^−/−^ *NRASQ61K* cells in vivo ([Figure 2F](#F2){ref-type="fig"}) and prior to transplantation ([Figure S3N](#SD1){ref-type="supplementary-material"}). We next investigated the link between the gene expression profile observed in *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells and genes that acquire H3K27me3 in the developmental transition from DN1 to DP ("DP_only_H3K27me3") as described previously ([@R71]). These PRC2 target genes are enriched in DN1 cells compared to DP cells ([Figure S3O](#SD1){ref-type="supplementary-material"}), consistent with a role for H3K27me3 in the maintenance of gene-repression during thymocyte development. We found this set of PRC2 target genes to also be enriched following *Ezh2*-inactivation in *Cdkn2a*^−/−^ *NRASQ61K* cells ([Figure 2G](#F2){ref-type="fig"} in vivo; [Figure S3P](#SD1){ref-type="supplementary-material"} in vitro). Importantly, one genomic site that is transcriptionally silenced in the transition from DN1 to DP cell and acquires H3K27me3 in this transition is the distal *HoxA* cluster ([Figure 2H](#F2){ref-type="fig"}). Thus, *Ezh2* inactivation results in enhanced expression of genes that are highly expressed in human ETP-ALL and in murine purified DN1 ETP cells. Furthermore, *Ezh2* inactivation promotes expression of genes that acquire H3K27me3 in normal T-lineage development.

Differentiation Block of *NRASQ61K* Cells Is Partially Relieved by Thymic Microenvironment in Cells with Intact PRC2, but Not Cells with *Ezh2* or *Eed* Inactivation {#S6}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------

Flow cytometric analysis of thymic fluorochrome-positive blasts demonstrated a significant proportion of CD4/CD8 DP blasts in recipients of cells with intact PRC2 function, but not recipients of *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* or *Eed*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* blasts ([Figure 3A](#F3){ref-type="fig"}). PRC2-compromised cells also showed a lower proportion of CD44^−^/CD25^−^ blasts ([Figure 3B](#F3){ref-type="fig"}) and a significantly higher proportion of CD44^+^/CD25^−^ (DN1- like) blasts ([Figure 3C](#F3){ref-type="fig"}). All groups had similar levels of CD4 single-positive blasts ([Figure 3D](#F3){ref-type="fig"}) and CD8 single-positive blasts ([Figure 3E](#F3){ref-type="fig"}) in the thymus. Levels of KIT were slightly, but significantly, higher in recipients of *Ezh2*^D/D^ cells ([Figure 3F](#F3){ref-type="fig"}). These data show that the thymic microenvironment partially alleviates the differentiation block of NRASQ61K cells in the presence of an intact PRC2 complex. The data further support the concept that PRC2 is important for thymic T cell differentiation and that impaired PRC2 function results in a differentiation block.

Genes Preferentially Marked by H3K27me3 in *Ezh2^f/f^* *Cdkn2a*^−/−^ *NRASQ61K* Are Transcriptionally Enriched in *Ezh2*^D/D^ Cells {#S7}
-----------------------------------------------------------------------------------------------------------------------------------

We performed chromatin immunoprecipitation sequencing (ChIP-seq) for H3K27me3 on cultured leukemias from recipients of *Ezh2^f/f^* and *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells. There was notable loss of K27me3 signal in Ezh2-inactivated cells at loci with strong positive signal in floxed counterparts ([Figure 4A](#F4){ref-type="fig"}). Using MACS2 ([@R15]), we identified 59,289 peaks (corresponding to 7,334 genes) for the *Ezh2^f/f^ Cdkn2a*^−/−^ *NRASQ61K* cells compared to 660 peaks (corresponding to 259 genes) in the *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells ([Table S1](#SD2){ref-type="supplementary-material"}). The H3K27me3-associated genes within both groups showed highly significant overlap with MSigDb gene sets consisting of established PRC2 targets, and the most significant hit for both groups in the entire MSigDb database was "BENPORATH_ES_WITH_H3K27ME3" (data not shown). A gene set defined as genes with differentially higher H3K27me3 signal in floxed cells was significantly enriched in *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells in vivo ([Figure 4B](#F4){ref-type="fig"}) and prior to injection (data not shown). We found significant overlap between genes losing H3K27me3 in *Ezh2*-inactivated cells and genes gaining H3K27me3 in the transition from DN1 to DP cells ([@R71]) ([Figure 4C](#F4){ref-type="fig"}).

Inactivation of *Ezh2* Accentuates a Stem- and Progenitor-Associated Transcriptional Program {#S8}
--------------------------------------------------------------------------------------------

Since ETP-ALL has been linked to stem cell transcriptional programs, we asked if inactivation of *Ezh2* leads to enrichment of stem-cell-associated transcriptional programs. We found that genes upregulated in human HSC (data from [@R40]; [Figure 5A](#F5){ref-type="fig"}) and genes upregulated in murine HSC (data from [@R6]; [Figure 5B](#F5){ref-type="fig"}) compared to more mature cell types are enriched in *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells in vivo. We found enrichment of the same gene sets in *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells prior to injection (data not shown) and interestingly also in publically available expression data in *Ezh2*^D/D^ compared to *Ezh2^f/f^* murine granulocyte-macrophage progenitors (GMPs) (data not shown) ([@R36]). These data provide additional evidence that *Ezh2* contributes to silencing of a stem-cell- and early-progenitor-cell-associated program in leukemic and normal hematopoiesis. We further confirmed increased expression of two stem-cell- and early-progenitor-cell-associated genes, *HoxA9* ([Figure 5C](#F5){ref-type="fig"}) and *Bmi1* ([Figure 5D](#F5){ref-type="fig"}), in response to *Ezh2* inactivation in vivo. These loci are PRC2 targets in *Ezh2^f/f^ Cdkn2a*^−/−^ *NRASQ61K* cells ([Figure 5E](#F5){ref-type="fig"}). In summary, these data show that developmental transcriptional downregulation of stem-cell- and early- progenitor-cell-associated genes is accompanied by gain of H3K27me3 at a number of critical loci. Genetic inactivation of *Ezh2* leads to impairment in the developmentally regulated downregulation of these stem-cell- and early-progenitor-cell-associated genes. Thus, acquisition of the *Ezh2*-catalyzed H3K27me3 is associated with transcriptional silencing of stem-cell-associated programs during hematopoietic differentiation.

Forced Expression of *HoxA9* Recapitulates Key Aspects of PRC2 Inactivation {#S9}
---------------------------------------------------------------------------

We confirmed that *HoxA9* is indeed a direct PRC2 target in our system using ChIP followed by qPCR ([Figure 6A](#F6){ref-type="fig"}). Furthermore, genes with expression levels that correlate with *HOXA9* expression in T-ALL (including ETP-ALL) and in acute myeloid leukemia were identified using Pearson correlation analysis on two independent publically available human leukemia datasets (GSE28703, [@R70]; and GSE689, [@R65]), as previously described ([@R64]). Both gene sets clustered murine LSKs, GMPs, and megakaryocyte-erythroid progenitors (MEPs) with 100% accuracy, based on published expression data ([@R25], [@R26]) ([Figure S4A](#SD1){ref-type="supplementary-material"}). Genes correlated with *HOXA9* in T-ALL or AML were significantly enriched in *Ezh2*^D/D^ versus *Ezh2^f/f^ Cdkn2a*^−/−^ *NRASQ61K* cells in vivo ([Figures 6B and 6C](#F6){ref-type="fig"}) and prior to injection ([Figures S4B and S4C](#SD1){ref-type="supplementary-material"}).

We next asked if the elevated expression of the late *HoxA*-cluster gene *HoxA9* has functional relevance in our leukemia model. We coexpressed *HoxA9*-IRES-GFP or empty-vector-IRES-GFP with *NRASQ61K* in *Ezh2^f/f^ Cdkn2a*^−/−^ LSK cells. Cells were expanded on OP9-DL1 stroma in the presence of cytokines, and transplanted into syngeneic, sublethally irradiated recipients. Leukemia latency was shortened significantly in the recipients of *HoxA9*-overexpressing cells ([Figure 6D](#F6){ref-type="fig"}). Overexpression of *HoxA9* was confirmed by qRT-PCR prior to injection ([Figure 6E](#F6){ref-type="fig"}). We also noted enrichment of *HOXA9*-correlated genes in human ETP-ALL with genomic alteration in a PRC2 component compared to ETP-ALL without genomic alteration in PRC2 components ([Figures S4D and S4E](#SD1){ref-type="supplementary-material"}; data from [@R70]).

*Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* Leukemias Show Accentuated Growth and Survival Signaling {#S10}
---------------------------------------------------------------------------------------------

While increased expression of a stem cell program, that includes HOXA cluster genes, explains a substantial portion of the phenotypic and transcriptional consequences of PRC2 inactivation, we also noted transcriptional evidence of increased growth and survival signaling in our transcriptome analysis. Dysregulated growth and survival signaling have previously been reported as a consequence of PRC2 inactivation. We performed gene set enrichment analysis (GSEA) in our ETP-ALL model and noted significant enrichment of growth factor and cognate receptor gene transcripts in *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* leukemias compared to floxed counterparts in vivo ([Figure S5A](#SD1){ref-type="supplementary-material"}) and in vitro (data not shown). In NF1 sarcomas, PRC2 inactivation has recently been linked to hyperactive RAS signaling and may occur at the chromatin level rather than through defined enhanced phospho-signaling ([@R11]). Indeed, we found RAS signatures accentuated in our model upon *Ezh2* inactivation ([Figure S5B](#SD1){ref-type="supplementary-material"} and data not shown). In addition, genes downregulated in NF1-associated sarcoma cell lines by reintroduction of *SUZ12* are enriched in our model upon *Ezh2*-inactivation ([Figure S5C](#SD1){ref-type="supplementary-material"}). Many of the genes deregulated in our model are documented targets of the STAT3 signaling pathway ([Figures S5D and S5E](#SD1){ref-type="supplementary-material"}). Furthermore, STAT3 is a critical component in myeloid development ([@R33]; [@R53]), in keeping with a myeloid surface marker phenotype in the *NRASQ61K* model. We therefore performed phospho-western blotting and documented increased phosphorylation of STAT3 on tyrosine residue 705 ([Figure 7A](#F7){ref-type="fig"}). This raised the intriguing possibility that PRC2 mutant ETP-ALL might be susceptible to JAK/STAT pathway inhibition even in the absence of mutations directly involved in the pathway.

*Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* Cells Respond to JAK/STAT Pathway Inhibition {#S11}
---------------------------------------------------------------------------------

Phosphorylation of STAT3 and STAT5 has been recently been documented in a majority of human ETP-ALL, and was reversed by the JAK1/2 inhibitor ruxolitinib ([@R31]). Activating mutations in cytokine receptors that signal through JAK/STAT are found at substantial frequencies in human ETP-ALL, providing a rationale for the use of ruxolitinib in these subtypes. While our model does not carry any mutations that would be expected to signal through JAK/STAT, the increased STAT3Y705 phosphorylation led us to assess whether this pathway is functionally important in our ETP-ALL model. We exposed *Ezh2^f/f^* and *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells in vitro to ruxolitinib and observed that ruxolitinib reverses STAT3Y705 phosphorylation in both cell types ([Figure 7B](#F7){ref-type="fig"}). In addition, ruxolitinib inhibited in vitro growth of *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* ([Figure 7C](#F7){ref-type="fig"}). However, the increased STAT3Y705 phosphorylation in *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* did not confer hypersensitivity to ruxolitinib. Rather, loss of PRC2 appeared to be a possible mechanism of resistance, with higher doses of ruxolitinib being required to fully block STAT3Y705 phosphorylation and affect cell growth. Similar results were found in a second set of leukemias ([Figure S5F](#SD1){ref-type="supplementary-material"}). *Eed*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells likewise had accentuated phospho-STAT3Y705 ([Figure S5G](#SD1){ref-type="supplementary-material"}) and showed cell growth inhibition in response to ruxolitinib ([Figure S5H](#SD1){ref-type="supplementary-material"}). To further investigate the role of JAK/STAT signaling in our model, we evaluated the effect of two published STAT3 inhibitors, LLL12 ([@R29]) and BP-1-102 ([@R72]). Both inhibited STAT3Y705 phosphorylation in *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells and interfered with their growth ([Figures S5I and S5J](#SD1){ref-type="supplementary-material"}). In summary, these data provide strong evidence for the functional importance of JAK/STAT signaling in our model and raise concerns that PRC2 loss may make clinically meaningful inhibition of JAK/STAT signaling more challenging.

De-repression of *Il6ra* Contributes to Hyperactive JAK/STAT Signaling in T-ALL with PRC2 Inactivation {#S12}
------------------------------------------------------------------------------------------------------

Finally, to better understand the mechanistic basis of the increased JAK/STAT signaling in *Ezh2*^D/D^ versus *Ezh2^f/f^* *Cdkn2a*^−/−^ *NRASQ61K* cells, we first asked whether STAT3 is transcriptionally upregulated in response to *Ezh2* inactivation. *Ezh2*^D/D^ cells displayed slightly higher levels of *Stat3* mRNA ([Figure S6A](#SD1){ref-type="supplementary-material"}), though the effect was small and not statistically significant. We therefore assessed the responsiveness of our paired leukemias to several growth factors (FLT3L, HGF, IL6, IL7, and SCF). We found no difference in the responsiveness to FLT3L, HGF, and SCF ([Figure S6B](#SD1){ref-type="supplementary-material"}). However, both IL6 and IL7 led to exaggerated STAT3Y705 phosphorylation, with a very pronounced increase for IL6 ([Figures 7D](#F7){ref-type="fig"} and [S6B](#SD1){ref-type="supplementary-material"}). *Il6ra* was significantly higher expressed in *Ezh2*-inactivated cells compared to floxed counterparts ([Figure 7E](#F7){ref-type="fig"}). This finding correlates with higher levels of H3K27me3 at the *Il6ra* locus in *Ezh2^f/f^* compared to *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* leukemia by ChIP-seq ([Figure 7F](#F7){ref-type="fig"}). *Il6ra* is transcriptionally downregulated in the transition from normal DN1 cells to DP cells, and the *Il6ra* locus acquires H3K27me3 in DP cells ([Figure 7F](#F7){ref-type="fig"}) ([@R71]). The IL6R is also significantly higher expressed in ETP-ALL compared to typical ALL in the St. Jude study ([@R70]) ([Figure 7G](#F7){ref-type="fig"}). Increased STAT3Y705 phosphorylation due to IL6 hyper-responsiveness thus contributes to increased JAK/STAT signaling in *Ezh2*^D/D^ T-ALL and may be a mediator of drug resistance to JAK1/2 inhibition in this model. Interestingly, we also observed an increase in STAT3Y705 phosphorylation in *Ezh2^f/f^* pre-leukemic and leukemic cells in HoxA9-overexpressing cells ([Figure S6C](#SD1){ref-type="supplementary-material"}), pointing toward a potential additional link between early hematopoietic transcriptional programs and accentuated signaling in our model.

DISCUSSION {#S13}
==========

The effects of PRC2 hyper- and hypoactivity in human disease and model systems have been contradictory. Hyperactive alleles of *EZH2* observed in human lymphomas contribute to differentiation block and lymphomagenesis in mouse models. Inactivation of *Ezh2* impedes the progression of *MLL*-*AF9* driven leukemia in mice ([@R37]; [@R60]), and inactivation of *Eed* is not tolerated ([@R37]; [@R52]). On the other hand, alterations in PRC2 components thought to be inactivating are associated with hematologic malignancies in hu- mans and mice. Recently, PRC2-mediated control of genes with opposing function on cellular growth has been demonstrated in normal murine hematopoiesis ([@R67]). Here, we provide evidence for the functional importance of *Cdkn2a* as an *Ezh2* downstream target in acute leukemia. Furthermore, our findings indicate that *Ezh2* has a functional role in the developmental silencing of a gene expression program associated with the transition of early thymic precursors to DP thymocytes and a transcriptional program associated with stem cells and early progenitor cells in normal hematopoiesis. We validated functional importance for one such gene, *HoxA9*, using an overexpression approach. Finally, we show that the prognostic implication of *Ezh2* alterations is in part explained by deregulated growth and survival signaling through STAT3, a signaling alteration also associated with other poor prognosis subsets of acute leukemia.

Control of Cdkns by *Ezh2* {#S14}
--------------------------

*Cdkn2a* is an established binding target of PRC2 and PRC1. Previous studies have demonstrated that the adverse effects on cellular growth resulting from inactivation of *Eed* and other Polycomb-group genes in hematopoiesis can be rescued in part by genetic inactivation of *Cdkn2a* ([@R19]; [@R42]; [@R67]). Here, we report that genetic inactivation of *Cdkn2a* allows for the establishment of *Ezh2* null acute leukemia. In human ETP-ALL, PRC2 components are frequently altered, but *CDKN2A* is deleted in a minority of cases ([@R18]; [@R70]). These data suggest that in human ETP-ALL, *CDKN2A* may be controlled by mechanisms other than deletional inactivation. In accord with this speculation, *CDKN2A* is a documented target of epigenetic silencing in human leukemia. It will be important to study how this locus is controlled in human ETP-ALL with impaired PRC2-function. Candidate mechanisms include DNA methylation, H3K9 methylation, and PRC1-dependent silencing.

*Ezh2* Contributes to Developmental Silencing of Genes Expressed in Early T Cell Precursors and in Stem Cells and Early Progenitor Cells {#S15}
----------------------------------------------------------------------------------------------------------------------------------------

The developmental transition from early thymic precursor to DP thymocyte has been well characterized. ETPs have been documented to retain myeloid development potential that is progressively lost in the transition to DP cell ([@R2]; [@R66]). The developmental transition is accompanied by the acquisition of H3K27me3 at many loci, including stem-cell-associated genes such as late *HoxA*-cluster genes and the receptor for IL6 ([@R71]). These findings are in keeping with a recently described role for PRC2 and Ikaros in regulating thymocyte development ([@R44]). In our *NRASQ61K* leukemia model, *Ezh2*-inactivation results in enriched expression of genes associated with DN1 cells, and therefore contributes to a differentiation block.

*Ezh2* Contributes to Developmental Silencing of Genes Highly Expressed in Early Hematopoiesis {#S16}
----------------------------------------------------------------------------------------------

We found that genes expressed in early hematopoiesis, such as HoxA9, Bmi1 ([Figure 5E](#F5){ref-type="fig"}), and Gata2 (data not shown), are PRC2 targets in our model. We also noted that these genes are silenced and acquire H3K27me3 in the developmental transition from immature LSK to GMP cells in published data (data not shown) ([@R3]). There is significant overlap in the genes acquiring H3K27me3 in the transition from LSK to GMP and in the transition from DN1 to DP, further supporting a role for Ezh2/PRC2 in the silencing of early transcriptional programs in hematopoietic differentiation ([Figure S7](#SD1){ref-type="supplementary-material"}). Epigenetic mechanisms have been implicated in the differentiation-associated silencing of genes highly expressed in the stem/early progenitor compartment. Examples are the H3K9 methyltransferase G9a ([@R7]) and the histone demethylase LSD1/KDM1a ([@R20]). Interestingly, G9A ([@R35]) and LSD1 have both been reported to collaborate with EZH2 ([@R62]). In human leukemia, stem cell gene expression signatures have been linked to inferior outcomes ([@R13]). ETP-ALL has previously been shown to express a stem cell program compared to non-ETP T-ALL ([@R70]). Our findings show that inactivation of the PRC2 component *Ezh2* directly results in the accentuation of an expression program associated with stem cells and early progenitor cells, suggesting a causal link. This is further supported by our findings that overexpression of the stem cell and early progenitor transcriptional regulator *HoxA9* recapitulates many aspects of PRC2 impairment in this model, including the key features of a more immature and accelerated disease in vivo. Despite its clear functional relevance, *HoxA9* is likely not the only component of this stem cell transcriptional program mediating the effect of PRC2 compromise, and other PRC2 target genes are attractive candidates for further study. A better understanding of the regulation of stem cell programs promises the development of more specific targeting of leukemic self-renewal, sparing normal hematopoietic cells.

Another model of human ETP-ALL has recently been published using transfer of *IL7R* mutants and *LMO2* into purified murine DN thymocytes ([@R61]). In this model, murine *p19*^−/−^ DN thymocytes rather than earlier hematopoietic progenitors or HSCs were the targets of transformation, and inactivation of PRC2 components was not employed. Nonetheless, a leukemic phenotype similar to what we describe was observed. These findings are in keeping with the reported genetic heterogeneity of human ETP-ALL ([@R70]).

Cooperation with and Accentuation of Growth and Survival Signaling by Inactivation of PRC2 {#S17}
------------------------------------------------------------------------------------------

In humans, *PRC2* alterations are frequently found in clinical acute leukemia samples with T cell/myeloid features ([@R16]; [@R70]): For example, in the study by Zhang, 5 of the 11 *NRAS*-mutant and 7 out of 7 *NF1* mutated ETP-ALL cases had an alteration in at least 1 PRC2 component. Genetic alterations impeding PRC2-function are also found in the megakaryoblastic leukemia (AMKL) observed in patients with Down Syndrome ([@R38]; [@R69]), and in juvenile myelo-monocytic AML (JMML), a RAS driven disease with pathognomonic activating mutation in *RAS* (mostly *NRAS* and *KRAS*) or inactivating mutations in *PTPN11* or *NF1* ([@R57]). Rare *EZH2*-alterations have been described in adult AML ([@R5]) (3 out of 200 analyzed samples) and, interestingly, 2 out of these 3 samples had co-occurring mutations in *KRAS* or *NRAS*. Very recently, cooperation between the RAS pathway and PRC2 inactivation has also been demonstrated for some solid tumors ([@R11]). These clinical and experimental data, together with our findings, support the concept that RAS signaling cooperates with PRC2 compromise in cellular transformation and support the relevance of our findings to human malignancy.

JAK/STAT signaling is emerging as an important pathogenic factor in hematopoietic malignancies. Mutations of *JAK* genes or the IL7 receptor have been implicated in T-lineage ALL ([@R12]; [@R70]). Hyperactivation of STAT3 in response to growth factors has been linked to inferior survival in human pediatric AML ([@R48]). Importantly, signaling abnormalities observed in human ETP-ALL, such as *SH2B3* alterations and *FLT3-ITD*, have been linked to hyperactive STAT3 signaling ([@R34]; [@R46]). Our data indicate that inactivation of *Ezh2* leads to accentuated phosphorylation of STAT3 on tyrosine 705, which was associated with an increase in expression of *Il6ra* and hypersensitive STAT3 phosphorylation in response to IL6.

Although we cannot completely rule out off-target effects, our studies using three different inhibitors of JAK/STAT signaling strongly suggest functional importance of JAK/STAT signaling in our model. These data are significant in several respects: (1) our findings directly link inactivation in an epigenetic modifier to a biochemical signaling change; (2) PRC2 inactivation simultaneously induces two poor prognostic features, a stem cell transcriptional signature and hyperactivation of STAT3 in response to growth factors, both independently linked to poor outcome; and (3) while the JAK/STAT pathway is clearly active and functional in our model, pharmacologic inhibition may be more challenging due to increased levels of STAT phosphorylation to be overcome. In addition, possibly alternate signaling pathways in addition to IL6/IL6RA, such as the accentuated RAS transcriptional signature, will need to be considered.

The relationship of STAT3 signaling and EZH2 is complex. EZH2-mediated methylation of STAT3 has been reported to be required for STAT3Y705 phosphorylation in glioma cells ([@R21]). In colon cancer cells, this dependency was not found, but EZH2-mediated methylation of STAT3 was found to be important for full induction of a subset of STAT3 target genes ([@R10]). Differences in cell type and experimental setup may account for these differences. In our model, inactivation of *Ezh2* resulted in a net positive enrichment of canonical STAT3 target genes ([Figures S5D and S5E](#SD1){ref-type="supplementary-material"}).

PRC2 As a Therapeutic Target in Cancer Therapy {#S18}
----------------------------------------------

Context dependence will need to be considered in the use of drugs targeting epigenetic modifiers: pharmacologic inhibition of EZH2 is a highly promising strategy in carefully selected target diseases ([@R22]; [@R23], [@R24]; [@R27]; [@R32]) and may have potential benefit in the treatment of *MLL*-rearranged leukemia ([@R9]; [@R37]; [@R52]; [@R60]; [@R68]). Our data provide additional evidence that rational selection of target diseases based on molecular features will be an important determinant of success for the next generation of epigenetic cancer therapies.

In summary, our data link inactivation of *Ezh2* to stem cell expression programs and to hyperactive cytokine signaling through STAT3, both features known to be associated with inferior clinical outcome. Our data clarify the role of *Ezh2* in ETP-ALL and support the use of therapies targeting JAK/STAT signaling, as recently suggested by Teachy and colleagues in ETP-ALL patient samples ([@R31]) and by Sorrentino and colleagues in a murine model of ETP-ALL ([@R61]). These prior studies did not investigate *Ezh2* mutant samples. Our data suggest that *EZH2*-mutated cases, which are specifically associated with poor clinical outcomes ([@R70]), may also potentially benefit from modulation of the JAK/STAT signaling pathway, especially if synergistic compounds can be identified. However, inhibiting the accentuated signaling may require somewhat higher doses in PRC2 mutant versus wild-type cells, and close attention will need to be paid in clinical studies to ensure target inhibition in this subgroup. Our work thus provides mechanistic insights into the association of PRC2 with poor prognostic features, and has critical implications for the study of JAK/STAT pathway inhibition in T-ALL.

EXPERIMENTAL PROCEDURES {#S19}
=======================

For published plasmids used, antibodies, primer sequences, gene sets, gene lists ([Table S1](#SD2){ref-type="supplementary-material"}), and additional experimental details, please refer to [Supplemental Experimental Procedures](#SD1){ref-type="supplementary-material"}.

Mice {#S20}
----

Animals were maintained at the Animal Research Facility at the University of Colorado Anschutz Medical Campus. Animal experiments were approved by the Internal Animal Care and Use Committee at the University of Colorado Denver Anschutz Medical Campus. All mice were maintained on a fully backcrossed C57BL/6 background. See [Supplemental Experimental Procedures](#SD1){ref-type="supplementary-material"} for mouse genotypes.

Generation of Transformed Murine Cells and Leukemia {#S21}
---------------------------------------------------

MSCV-Ras-pgk-puro was created by subcloning human *NRASQ61K* sequences (Addgene plasmid 12543, Channing Der lab) as a BamH1 fragment into the MSCV-puro vector. See [Supplemental Experimental Procedures](#SD1){ref-type="supplementary-material"} for published plasmids. LIN^−^SCA1 ^+^KIT^+^ (LSK-) cells were sorted from donor bone marrow using a MoFlo flow sorter (Beckman Coulter) were prestimulated in liquid culture in the presence of murine SCF (20 ng/ml), FLT3L (20 ng/ml), IL6 (20 ng/ml), and TPO (10 ng/ml) (Peprotec) and then transduced on Retronectin-coated (Takara) plates. Cells were sorted for expression of *GFP* or *YFP* and were selected in the presence of Puromycin on OP9-DL1 cells carrying a resistance gene for puromycin in the presence of FLT3L (5 ng/ml), SCF (5 ng/ml), and IL7 (1 ng/ml). Cells expanded for 14--21 days were then injected into syngeneic sublethally (600 cGy) irradiated recipients. Cell growth and viability were followed by serial cell counts. Antibodies used for flow cytometry and immunoblot detection and qPCR primers are detailed in [Supplemental Experimental Procedures](#SD1){ref-type="supplementary-material"}.

Western Blotting {#S22}
----------------

Proteins for histone blots were harvested using acid extraction (see [Supplemental Experimental Procedures](#SD1){ref-type="supplementary-material"}). Proteins for non-histone protein blots were harvested using RIPA-buffer including cOmplete mini protease inhibitor cocktail (Roche) and, for phospho-blots, phosSTOP phosphatase inhibitor (Roche), according to the manufacturer\'s instructions. Protein was separated on a 10% Bis-Tris Gel (Nupage; Invitrogen) and blotted using the "iblot" dry transfer system (Invitrogen).

qRT-PCR {#S23}
-------

qRT-PCR was used to confirm expression of candidate genes identified by RNA sequencing. RNA was harvested from NRASQ61K-transformed sorted fluorochrome-positive (GFP for *Ezh2^f/f^* and *Eed^f/f^* and YFP for *Ezh2*^D/D^ and *Eed*^D/D^) blasts isolated from leukemic spleens, using RNeasy mini columns (QIAGEN). Individual RNA samples were reverse transcribed and qRT-PCR was run in triplicate using SYBR green. Ratios were calculated using the method described by Pfaffl ([@R47]). The Student\'s t test was performed on log-transformed ratios of gene of interest/internal control (*Hprt*) using GraphPad 6 software.

Chromatin Immunoprecipitation followed by Next-Generation Sequencing {#S24}
--------------------------------------------------------------------

ChIP for H3K27me3 in murine leukemias was performed using rabbit monoclonal antibody clone (C36B11) from Cell Signaling similarly as described elsewhere ([@R37]). ChIP DNA libraries were made using the Nugen Ovation Ultralow system V2, followed by next-generation sequencing on an Illumina HiSeq2000 at the Genomics Core of the University of Colorado Anschutz Campus. See [Supplemental Experimental Procedures](#SD1){ref-type="supplementary-material"} for details on data analysis.

Gene Set Enrichment Analysis {#S25}
----------------------------

GSEA was performed as described previously ([@R59]) using pre-ranked gene lists as input files. Construction of gene sets used is described in [Supplemental Experimental Procedures](#SD1){ref-type="supplementary-material"}, and the gene sets are listed in [Table S1](#SD2){ref-type="supplementary-material"}.
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![Genetic Inactivation of *Ezh2 or Eed* Cooperates with *NRASQ61K* in the Establishment of Murine Leukemia\
(A) Experimental schema.\
(B) Inactivation of *Ezh2* results in global decrease in cellular H3K27me3 (western blot).\
(C) Significantly shortened survival in recipients of *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells compared to floxed counterparts (n = 10 mice per group; Kaplan-Meier analysis).\
(D) Significantly shortened survival in recipients of *Eed*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells compared to floxed counterparts (n = 10 mice per group; Kaplan-Meier analysis).\
(E) Direct comparison shows similar survival in recipients of *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells and recipients of *Eed*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells (n = 10 mice per group; Kaplan-Meier analysis). NS, not significant.\
See also [Figures S1 and S2](#SD1){ref-type="supplementary-material"}.](nihms-761377-f0002){#F1}

![*NRASQ61K* Leukemia Has Phenotypic Features of ETP-ALL and *Ezh2* Controls a Gene Expression Program Characteristic of ETP-ALL and of Physiologic Murine Early Thymic Precursors\
(A) Higher proportion of cells double positive (DP) for myeloid markers MAC1 and GR1 in *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells compared to floxed counterparts. Non-significant trend toward higher MAC1/GR1 DP cells in *Eed*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells compared to floxed counterparts.\
(B) A majority of splenic *NRASQ61K* leukemic blasts are CD44^+^/CD25^−^ in all groups.\
(C and D) Comparable subset positive expression of CD5 (C) and KIT (D) in all three groups.\
(E) Genes highly expressed in human ETP-ALL compared to typical T-ALL are transcriptionally enriched in vivo in *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells compared to floxed counterparts.\
(F) Genes highly expressed in mouse DN1 cells compared to DP cells ("DN1vsDP_up" gene set) are transcriptionally enriched in vivo in *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells.\
(G) Genes that acquire H3K27me3 in the transition from the DN1 to the DP stage ("DP_only\_ H3K27me3" gene set) are transcriptionally enriched in vivo in *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K*.\
(H) ChIP-seq peaks in physiological DN1 and DP cells visualized for the genomic locus for the stem cell-associated late *HoxA* cluster as an examples of genes that acquire H3K27me3 in the developmental transition from DN1 to DP (data from [@R71]).\
Error bars represent SD. \*p \< 0.05. NS, not significant. See also [Figure S3](#SD1){ref-type="supplementary-material"}.](nihms-761377-f0003){#F2}

![Differentiation Block Is Partially Reversed in the Thymus in *NRASQ61K* Cells with a Fully Functional PRC2 Complex, but Not in *Ezh2*^D/D^ and *Eed*^D/D^ *NRASQ61K* Cells\
(A) Significantly higher proportion of CD4/8 DP fluorochrome-positive blasts in the thymus of recipients of *Cdkn2a*^−/−^ *NRASQ61K* cells with a fully functional PRC2.\
(B) Significantly lower proportion of CD44^−^/CD25^−^ blasts in the thymus of recipients of *Ezh2*^D/D^ and *Eed*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells.\
(C) Significantly higher proportion of CD44^+^/CD25^−^ blasts in the thymus of recipients of *Ezh2*^D/D^ and *Eed*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells.\
(D) Similar proportion of CD4 single-positive (SP) blasts in the thymus of recipients of *NRASQ61K* cells with a fully functional PRC2 and recipients of *Ezh2*^D/D^ and *Eed*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells.\
(E) Similar proportion of CD8 single-positive blasts in the thymus of recipients of *NRASQ61K* cells with a fully functional PRC2 and recipients of *Ezh2*^D/D^ and *Eed*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells.\
(F) Similar proportion of KIT positive blasts in the thymus of recipients of *NRASQ61K* cells with a fully functional PRC2 and recipients of *Ezh2*^D/D^ and *Eed*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells (with the *Eed*^D/D^ group showing a small but significant increase compared to *Ezh2*^D/D^ group).\
Error bars represent SD. \*p \< 0.05. NS, not significant.](nihms-761377-f0004){#F3}

![H3K27me3 Changes Correlate with Transcriptional Differences between *Ezh2^f/f^* and *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* Cells\
(A) H3K27me3 differences between *Ezh2^f/f^* and *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells (top 5,000 genes). The ranked list of the top 5,000 genes is provided in [Table S1](#SD2){ref-type="supplementary-material"}.\
(B) Enrichment of genes with decrease in H3K27me3 in *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells.\
(C) Significant overlap between genes with loss of H3K27me3 after inactivation of *Ezh2* and genes acquiring H3K27me3 in the transition from mouse DN1 to mouse DP cells.\
See also [Figure S7](#SD1){ref-type="supplementary-material"}.](nihms-761377-f0005){#F4}

![PRC2 Controls a Stem Cell/Early Progenitor Cell Gene Expression Program in Hematopoietic Differentiation\
(A) Genes highly expressed in human hematopoietic stem cells are enriched in vivo in *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells compared to their floxed counterparts.\
(B) Genes highly expressed in mouse hematopoietic stem cells are enriched in vivo in *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells compared to their floxed counterparts.\
(C) *HoxA9* is significantly higher expressed in vivo in *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells compared to their floxed counterparts (Ezh2^f/f^ n = 3, Ezh2^D/D^ n = 4, qRT-PCR).\
(D) *Bmi1* is significantly higher expressed in vivo in *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells compared to their floxed counterparts (Ezh2^f/f^ n = 3, Ezh2^D/D^ n = 4, qRT-PCR).\
(E) ChIP-seq peaks visualized for the genomic locus for the stem-cell-associated late *HoxA*-cluster and the stem-cell-associated gene *Bmi1* as examples of genes that lose H3K27me3 after inactivation of Ezh2.\
Error bars represent SD. \*p \< 0.05.](nihms-761377-f0006){#F5}

![Accentuation of a Developmentally Regulated *HOXA9*-Correlated Gene Expression in *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* Cells\
(A) Increased H3K27me3 enrichment as measured by ChIP-qPCR at loci for *HoxA9* and the documented PRC2 target *Olig2*, but not b-actin, in *Ezh2^f/f^ Cdkn2a*^−/−^ *NRASQ61K* cells compared to *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells.\
(B) Genes correlated with *HOXA9* expression in T-ALL are transcriptionally enriched in vivo in *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells compared to their floxed counterparts.\
(C) Genes correlated with *HOXA9* expression in AML are transcriptionally enriched in *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells compared to their floxed counterparts.\
(D) Forced expression of *HoxA9* synergizes with *NRASQ61K* in leukemogenesis in the presence of an intact *Ezh2* locus.\
(E) Increased expression of *HoxA9* in MSCV-HoxA9-i-GFP (HOXA9) compared to MSCV-i-GFP (MIG) transduced cells (qRT-PCR).\
Error bars represent SD. \*p \< 0.05. See also [Figure S4](#SD1){ref-type="supplementary-material"}.](nihms-761377-f0007){#F6}

![*Ezh2*-Inactivation Leads to Accentuated Growth/Survival Signaling in *NRASQ61K* Leukemia\
(A) Phospho-western blotting reveals increased STAT3Y705 phosphorylation in *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells compared to their floxed counterparts.\
(B) STAT3Y705 phosphorylation is inhibited by ruxolitinib in a dose-dependent manner in *Ezh2^f/f^ Cdkn2a*^−/−^ *NRASQ61K* and *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells.\
(C) Growth of *Ezh2^f/f^ Cdkn2a*^−/−^ *NRASQ61K* and *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells is inhibited by ruxolitinib in a dose-dependent manner.\
(D) Exaggerated response to IL6 stimulation in *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells growth factor starved for 8 hr.\
(E) Increased level of *Il6ra* expression in *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells.\
(F) Increased H3K27me3 at the *Il6ra* locus in *Ezh2^f/f^ Cdkn2a*^−/−^ *NRASQ61K* cells compared to *Ezh2*^D/D^ *Cdkn2a*^−/−^ *NRASQ61K* cells and in normal mouse DP cells compared to DN1 cells.\
(G) Significantly increased *IL6RA* expression in human ETP-ALL compared to non-ETP ALL.\
Error bars represent SD. \*p \< 0.05. NS, not significant. See also [Figures S5 and S6](#SD1){ref-type="supplementary-material"}.](nihms-761377-f0008){#F7}
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1.  d Genetic inactivation of *Ezh*2 or *Eed* cooperates with *NRASQ61K* in leukemogenesis

2.  d Inactivation of *Ezh2* enhances a stem-cell-related transcriptional program

3.  d Inactivation of *Ezh2* results in increased STAT3 activation via Y705 phosphorylation
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